NEXGEL (NXGL) Planet MicroCap Showcase: VEGAS 2025 summary
Event summary combining transcript, slides, and related documents.
Planet MicroCap Showcase: VEGAS 2025 summary
3 Feb, 2026Business overview and growth strategy
Operates in three divisions: consumer products, contract manufacturing, and medical devices, with a focus on hydrogel technology for medical and cosmetic applications.
Expanded customer base includes major healthcare and consumer companies, fueling over 100% year-over-year growth for the past three years.
Facility in Pennsylvania features a rare electron beam accelerator for hydrogel production; packaging operations expanded in Texas with a new clean room.
Strategic partnerships and acquisitions, such as Kenkoderm and Silly George, have driven product and revenue diversification.
No company debt, with a focus on reducing cash burn and approaching EBITDA positive status.
Product innovation and pipeline
Medical device pipeline includes time-release drug patches and a human trial for an Apremilast patch targeting stubborn psoriasis lesions.
Consumer brands include MediGel, Kenkoderm (expanding to eczema products), and Silly George (eyelash and beauty products), with significant sales growth and new product launches planned.
SilverSeal, an antimicrobial wound and burn product, is now distributed through Cintas, increasing brand recognition and recurring revenue.
Partnership with STADA has exceeded projections, with new product launches and a growing U.S. platform.
Supplying gel pads for AbbVie's RESONIC cellulite treatment, with future revenue potential as the product launches.
Market positioning and competitive advantages
High water content, biocompatible hydrogels differentiate the company from competitors, making it the default choice for sensitive skin and medical applications.
U.S. manufacturing and tariff changes have made products more competitive against foreign UV gel manufacturers.
Custom and white label manufacturing offers expansion opportunities for partners in dermatology, beauty, and drug delivery markets.
Ongoing studies and commercial orders for gels used in laser hair removal and carcinogenic plume reduction, with potential for broader applications.
Marketing strategies are platform-specific, leveraging in-house analytics and external agencies to optimize direct-to-consumer sales.
Latest events from NEXGEL
- Q1 2025 revenue up 121% to $2.81M, gross margin at 42.4%, and net loss narrowed.NXGL
Q1 20259 Jul 2026 - Record Q2 revenue of $1.44M, with strong outlook driven by branded and Silly George growth.NXGL
Q2 20248 Jul 2026 - Surgeon-focused platform leverages strategic assets and partnerships to drive innovation and growth.NXGL
Investor presentation24 Jun 2026 - Expanded regenerative medicine portfolio and direct sales force set stage for rapid growth.NXGL
Planet MicroCap Las Vegas 202617 Jun 2026 - Shareholders will vote on director elections, share issuances, reincorporation, and key governance changes.NXGL
Proxy filing9 Jun 2026 - Annual meeting seeks approval for director elections, stock issuance, reincorporation, and capital changes.NXGL
Proxy filing29 May 2026 - Major acquisition expected to triple annual revenue and improve profitability.NXGL
Q1 202615 May 2026 - Revenue up 31.5% to $11.4M, but net loss of $3.0M and going concern risks persist.NXGL
Q4 202523 Apr 2026 - Acquisition and partnership triple revenue, drive profitability, and expand into regenerative medicine.NXGL
M&A announcement21 Apr 2026